CARA Valuation

Cara Therapeutics Inc

Add to Watchlist

Advanced Chart

4.900

+0.035(+0.720%)

Overview
Forecast
Valuation

CARA Relative Valuation

CARA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CARA is overvalued; if below, it's undervalued.

Historical Valuation

Cara Therapeutics Inc (CARA) is now in the Fair zone, suggesting that its current forward PS ratio of 6.18 is considered Fairly compared with the five-year average of 13.94. The fair price of Cara Therapeutics Inc (CARA) is between 2.85 to 5.02 according to relative valuation methord.

Relative Value

Fair Zone

2.85-5.02

Current Price：4.90

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-4.88

P/B

Median3y

4.31

Median5y

4.20

-278.48

FCF Yield

Median3y

-184.18

Median5y

-112.56

Competitors Valuation Multiple

The average P/S ratio for CARA's competitors is 4.94, providing a benchmark for relative valuation. Cara Therapeutics Inc Corp (CARA) exhibits a P/S ratio of 6.18, which is 25.19% above the industry average. Given its robust revenue growth of -51.56%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

CARA.O

Cara Therapeutics Inc